A detailed history of Braidwell LP transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Braidwell LP holds 2,098,866 shares of APLS stock, worth $57.5 Million. This represents 3.75% of its overall portfolio holdings.

Number of Shares
2,098,866
Previous 3,125,183 32.84%
Holding current value
$57.5 Million
Previous $90.1 Billion 99.93%
% of portfolio
3.75%
Previous 2.55%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025

SELL
$26.18 - $35.42 $26.9 Million - $36.4 Million
-1,026,317 Reduced 32.84%
2,098,866 $67 Million
Q3 2024

Nov 14, 2024

BUY
$28.84 - $41.15 $72.5 Million - $103 Million
2,513,383 Added 410.82%
3,125,183 $90.1 Billion
Q2 2024

Aug 14, 2024

BUY
$38.07 - $59.71 $23.3 Million - $36.5 Million
611,800 New
611,800 $23.5 Billion
Q4 2022

Feb 14, 2023

BUY
$43.24 - $61.04 $16.8 Million - $23.8 Million
389,596 New
389,596 $20.1 Billion

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.01B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Braidwell LP Portfolio

Follow Braidwell LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Braidwell LP, based on Form 13F filings with the SEC.

News

Stay updated on Braidwell LP with notifications on news.